Abstracts tagged "clinical research and interleukins (IL)"

Abstract Number: 1869 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Karel Pavelka², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Yi Wang⁷, Brian Porter⁸, Anna Stefanska⁹, Susanne Rohrer¹⁰ and Hanno Richards¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²1st Faculty of Medicine, Charles University, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, MEDICAL PLUS s.r.o.,, Uherske Hradiste, Czech Republic, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Ireland Limited, Dublin, Ireland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 3 study, which…